STAT
DECEMBER 5, 2023
WASHINGTON — Pfizer has decided to leave the Biotechnology Innovation Organization, according to two sources familiar with the decision. The departure is a blow to BIO, which represents members ranging from small biotech startups to massive pharmaceutical companies. The group on Tuesday announced its new CEO, rare disease advocate and biotech executive John Crowley.
Pharma Times
DECEMBER 5, 2023
The platform safely and effectively replicates the electric signalling process compounds - News - PharmaTimes
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
DECEMBER 5, 2023
CVS Health is promising to simplify how its pharmacies get paid for drugs. But that doesn’t mean the drugs will get cheaper. The country’s biggest pharmacy chain said it’s switching to a system where pharmacy benefit managers, employers, and other insurers pay for drugs based on the cost of the drug plus a set markup and dispensing fee.
Pharma Times
DECEMBER 5, 2023
Millions of people in the UK are set to benefit from the second wave of funding - News - PharmaTimes
Speaker: Jennifer Hill
Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.
STAT
DECEMBER 5, 2023
Eight months into his tenure, Johnson & Johnson’s R&D chief is putting a big emphasis on medicines for cancer, treatment-resistant depression, and autoimmune disease. To sharpen that focus, R&D chief John Reed told STAT that the company is de-emphasizing two areas that have been mainstays for the drug and medical device giant: infectious disease and vaccines, as well as medicines targeting kidney disease and rare eye conditions.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
STAT
DECEMBER 5, 2023
Here are two things that are true. The world needs more effective flu vaccines. And pharmaceutical companies that learned of the vaccine-making power of the messenger RNA platform during the Covid-19 pandemic need new markets for their technology.
PharmaVoice
DECEMBER 5, 2023
Apps, VR and more could play an increasingly vital role in the wider goals of creating value-based treatments — if the industry can get payers to sign on.
STAT
DECEMBER 5, 2023
WASHINGTON — The Biotechnology Innovation Organization has chosen longtime biotech executive and rare disease advocate John Crowley as its new CEO, the organization announced Tuesday. Crowley came to biotech when his children were diagnosed with a rare genetic neuromuscular disease. He started working at Bristol-Myers Squibb, and started Novazyme, which was eventually successful in creating an enzyme replacement therapy for Pompe disease.
pharmaphorum
DECEMBER 5, 2023
Reinvigorating the Cancer Moonshot with empowered patients Mike.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
STAT
DECEMBER 5, 2023
NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines? Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030. Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.
PharmExec
DECEMBER 5, 2023
TAR-200 has a novel targeted releasing system for the treatment of patients with Bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer who are ineligible for bladder removal surgery.
STAT
DECEMBER 5, 2023
WASHINGTON — Members of the Senate Finance Committee took their first steps today toward using Medicare payment policy to fix drug shortages. Drug shortages are particularly vexing because they’re mostly caused by policies within the control of the government, as opposed to outside shocks such as natural disasters. Instead, it’s economic factors — the complicated way Medicare pays hospitals or the dominance of group purchasing organizations that buy hospital drugs &#x
pharmaphorum
DECEMBER 5, 2023
In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh speaks with Ari Tulla, CEO and co-founder of Elo Health, about his ‘big vision’ to transform food – changing it from a leading cause of disease to the medicine it can be.
Advertisement
Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.
STAT
DECEMBER 5, 2023
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.
European Pharmaceutical Review
DECEMBER 5, 2023
Results from Geron’s Phase III IMerge trial evaluating its first-in-class investigational telomerase inhibitor imetelstat, have shown long-term and durable response in participants with a rare haematologic malignancy. Efficacy of the treatment was compared to placebo in patients with lower risk myelodysplastic syndromes (MDS) relapsed/refractory or ineligible for erythropoiesis stimulating agents (ESAs).
STAT
DECEMBER 5, 2023
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, everyone. Damian here with a special thanks to everyone who joined us for STAT’s live event in New York City last night. Today we have a sober look at the future of mRNA, a plot to bring CAR-T back to its founding ideals, and the downside of a billion-dollar buyout.
The Pharmacist
DECEMBER 5, 2023
Community Pharmacy England (CPE) is reaching out on both sides of the political divide to call for greater support for the pharmacy sector. CPE has written to both the health secretary, Victoria Atkins, and her Labour shadow, Wes Streeting, urging political leaders to work with the sector, patient bodies and charities to ‘realise the potential’ […] The post Fresh call for greater sector support from political health leaders appeared first on The Pharmacist.
Speaker: Joe Sharpe and James Carlson
Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.
Pharmaceutical Technology
DECEMBER 5, 2023
Professor Timothy Mackey talks about the recent reports of fraudulent Ozempic pens and the challenges in chasing drug counterfeiters.
pharmaphorum
DECEMBER 5, 2023
BMS chases MSD/Seagen with first-line bladder cancer filing Phil.
European Pharmaceutical Review
DECEMBER 5, 2023
Roche has agreed to acquire biotech Carmot Therapeutics for an upfront purchase price of $2.7 billion, enabling the Swiss pharma company to add a range of incretin treatments for obesity and diabetes to its portfolio. Incretins are “gut hormones that are secreted after food intake and play a role in modulating blood glucose by stimulating insulin secretion and suppressing appetite,” Roche highlighted.
pharmaphorum
DECEMBER 5, 2023
Roche bounces back in PIK3 with inavolisib data Phil.
Advertisement
Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.
European Pharmaceutical Review
DECEMBER 5, 2023
With the UK set to become an associated country to Horizon Europe on 1 January 2024, the political agreement on UK’s association to Horizon Europe has been adopted. Now, this final step in the process has been implemented by the EU-UK Specialised Committee on Participation in Union Programmes (SCPUP), the European Commission (EC) has announced. The programme is the EU’s key funding initiative for research and innovation with a budget of €95.5 billion for 2021-27.
pharmaphorum
DECEMBER 5, 2023
The pharma industry and the UK government may have reached an accord on the voluntary scheme of rebates used to limit rises in medicines spending in the UK, but the alternative statutory scheme remains a prickly subject.
The Pharmacist
DECEMBER 5, 2023
The overall pass rate from November 2023’s registration assessment for pharmacists was 66%, the General Pharmaceutical Council (GPhC) and Pharmaceutical Society of Northern Ireland (PSNI) have revealed. The figure represents a significant 10% rise on the previous year’s overall pass rate. A total of 1,067 candidates across the four UK countries sat the assessment on […] The post Pass rate for pharmacist registration exam up 10% in a year appeared first on The Pharmacist.
Express Pharma
DECEMBER 5, 2023
Sentynl Therapeutics, a US-based biopharma company wholly-owned by Zydus Lifesciences announced the execution of an assignment and assumption agreement with Cyprium Therapeutics, a Fortress Biotech subsidiary company. Under the agreement, Cyprium completed the transfer of its worldwide proprietary rights and US FDA documents pertaining to CUTX-101, the copper histidinate product candidate for the treatment of Menkes disease, to Sentynl.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
DECEMBER 5, 2023
Alto hits a high note with AI-driven depression therapy Phil.
Drug Patent Watch
DECEMBER 5, 2023
This chart shows the pharmaceutical companies with the most implant dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most implant dosed drugs… The post Which pharmaceutical companies have the most implant dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
Express Pharma
DECEMBER 5, 2023
Lupin has received approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application for Varenicline Tablets, 0.5 mg and 1 mg, to market a generic equivalent of Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. The product will be manufactured at Lupin’s Pithampur facility in India. Varenicline Tablets, 0.5 mg and 1 mg are indicated for use as an aid to smoking cessation treatment.
Expert insights. Personalized for you.
363 
Let's personalize your content